Your browser doesn't support javascript.
loading
MiR-151a: a robust endogenous control for normalizing small extracellular vesicle cargo in human cancer.
Burdiel, Miranda; Jiménez, Julia; Rodríguez-Antolín, Carlos; García-Guede, Álvaro; Pernía, Olga; Sastre-Perona, Ana; Rosas-Alonso, Rocío; Colmenarejo, Julián; Rodríguez-Jiménez, Carmen; Diestro, María Dolores; Martínez-Marín, Virginia; Higueras, Oliver; Cruz, Patricia; Losantos-García, Itsaso; Peinado, Héctor; Vera, Olga; de Castro, Javier; Ibáñez de Cáceres, Inmaculada.
Afiliación
  • Burdiel M; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • Jiménez J; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
  • Rodríguez-Antolín C; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • García-Guede Á; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
  • Pernía O; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • Sastre-Perona A; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
  • Rosas-Alonso R; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • Colmenarejo J; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
  • Rodríguez-Jiménez C; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • Diestro MD; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
  • Martínez-Marín V; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • Higueras O; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
  • Cruz P; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • Losantos-García I; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
  • Peinado H; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • Vera O; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
  • de Castro J; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
  • Ibáñez de Cáceres I; Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain.
Biomark Res ; 11(1): 94, 2023 Oct 20.
Article en En | MEDLINE | ID: mdl-37864266
ABSTRACT
Small extracellular vesicles (sEVs) in the blood of cancer patients contain higher amounts of tumor markers than those identified as free-circulating. miRNAs have significant biomedical relevance due to their high stability and feasible detection. However, there is no reliable endogenous control available to measure sEVs-miRNA content, impairing the acquisition of standardized consistent measurements in cancer liquid biopsy. In this study, we identified three miRNAs from a panel of nine potential normalizers that emerged from a comprehensive analysis comparing the sEV-miRNA profile of six lung and ovarian human cancer cell lines in the absence of or under different conditions. Their relevance as normalizers was tested in 26 additional human cancer cell lines from nine different tumor types undergoing chemotherapy or radiotherapy treatment. The validation cohorts were comprised of 242 prospective plasma and ascitic fluid samples from three different human tumor types. Variability and normalization properties were tested in comparison to miR-16, the most used control to normalize free-circulating miRNAs in plasma. Our results indicate that miR-151a is consistently represented in small extracellular vesicles with minimal variability compared to miR-16, providing a novel normalizer to measure small extracellular vesicle miRNA content that will benefit liquid biopsy in cancer patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomark Res Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomark Res Año: 2023 Tipo del documento: Article País de afiliación: España